Handok will pay an upfront fee and milestones.
Handok Pharmaceuticals has gained the exclusive rights to AmpliMed’s Phase II cancer drug for distribution in Korea. Handok will pay an upfront fee and milestone fees based on the achievement of certain development and regulatory goals.
The compound under consideration, Amplimexon, is designed to increase oxidative stress in tumor cells, leading to mitochondrial damage and apoptosis.
AmpliMed is conducting a Phase II trial evaluating Amplimexon plus gemcitabine vs. gemcitabine plus placebo in approximately 124 chemotherapy naive patients with metastatic pancreatic cancer. The company anticipates having survival results from the trial by the end of 2009.
“In addition to our ongoing Phase II trial in pancreatic cancer, we plan to start a Phase II trial of Amplimexon in combination with taxotere in patients with non-small-cell-lung cancer later this year,” says Robert T. Dorr, Ph.D., CEO of AmpliMed.
